A CDX2-positive result means tumor cells stained for a marker associated with intestinal differentiation; it does not, by itself, prove that a tumor began in the colon. A negative result does not rule out colorectal cancer. The pathologist interprets the staining pattern alongside the tumor’s appearance, specimen site, other stains, and clinical information.
What CDX2 immunohistochemistry measures
CDX2 is a transcription factor associated with intestinal epithelial differentiation. In a pathology report, “CDX2” usually refers to an immunohistochemistry (IHC) stain used to assess whether cells in a tissue specimen show this marker. A positive result means the tumor cells show staining according to the laboratory’s assay and scoring criteria; a negative result means they do not show the expected staining under those criteria.
As an Amazon Associate I earn from qualifying purchases.
The stain is evidence about the tumor’s characteristics, not a diagnosis by itself. In a tumor that already appears to be an adenocarcinoma, CDX2 expression can support intestinal differentiation and may contribute to considering a colorectal or another intestinal primary. The stain does not independently establish the tumor’s primary site, stage, prognosis, or treatment plan.
Mayo Clinic Laboratories cautions that “Interpretation of this test should be performed in the context of the patient’s clinical history and other diagnostic tests by a qualified pathologist.” Its test catalog describes technical stain performance; it does not provide a pathologist’s interpretation of an individual patient’s result.
#1 Best Overall
- [Ultra-Lightweight Ear Buds Designed for Small Ears] Each earbud weighs only 3.7g and features a compact, ergonomic in-ear design made especially for small ears. Secure, low-profile, and comfortable for workouts, all-day wear or overnight sleeping.The ultra-slim profile sits flush in your ear with no hard edges poking or rubbing, so you can even sleep on your side without discomfort.
- [Immersive Stereo Sound with TOZO OrigX Technology] TOZO OrigX tuning delivers clear vocals, balanced mids, and natural stereo sound for music, podcasts, and videos.
- [Long Battery Life for Daily Use] Get up to 7 hours of playtime on a single charge, with up to 32 hours total using the charging case—ideal for workdays, commuting, and extended listening sessions.
- [Bluetooth 5.3 & Stable Connection] Bluetooth 5.3 provides fast pairing, stable wireless performance, and reduced dropouts as you move around home or office.
- [Deep Bass with Clear Vocals] High-performance drivers produce punchy bass while keeping vocals clean and detailed for everyday listening.
In other words, the stain asks whether the cells in the sampled tissue display a particular marker under the laboratory’s testing conditions. It does not answer every question a reader may have after seeing the word “positive.” A marker can be useful to a pathologist without being unique to one cancer type or body site. The importance of the result comes from how well it fits the rest of the findings, not from the word “positive” alone.
What “positive,” “negative,” and “focal” mean
Read the result wording as a description of staining in the tested specimen, not as a stand-alone declaration of where the cancer began. The precise meaning depends partly on the laboratory’s method and criteria.
| Report wording | What it describes | How to interpret it |
|---|---|---|
| Positive | Tumor-cell staining is present under the laboratory’s criteria. | It can support intestinal differentiation in context. It does not prove a colorectal primary, because CDX2 is not exclusive to colorectal tumors. |
| Negative | Tumor cells lack the expected staining under the laboratory’s criteria. | It removes one possible line of support for intestinal differentiation, but cannot independently exclude colorectal cancer. |
| Focal or patchy | Staining is present in only some tumor cells or areas. | The significance depends on the specimen, controls, assay, and laboratory criteria. Check the pathologist’s interpretation rather than treating the term as a universal score. |
Why the pattern matters
Pathologists may consider where staining occurs, how extensive it is, and how strong it appears, as well as whether the laboratory’s controls behaved as expected. A result that mentions “patchy” or “focal” staining is not necessarily equivalent to a simple positive or negative in every laboratory’s reporting system.
Recommended Free Tools
For example, a 2023 colorectal carcinoma study described an approach in which any nuclear staining—even if patchy—counted as no loss when internal controls were positive. That is an interpretation approach reported in that study, not a rule to apply to every laboratory or every report. If the report does not explain how focal staining was classified, ask the care team or pathologist how the laboratory interpreted the pattern.
This distinction matters because a report may describe the observed pattern and then give an interpretation using the laboratory’s own criteria. One report’s use of “focal,” “patchy,” or “positive” should not automatically be mapped onto another laboratory’s scoring system. If the technical wording and the final diagnosis seem difficult to reconcile, ask whether the pathologist considered the stain positive, whether controls were satisfactory, and what significance was assigned to the extent of staining.
Controls are part of interpreting an immunostain: they help the laboratory and pathologist assess whether the stain behaved as expected in the tested material. The 2023 example specifically tied its approach to positive internal controls. A reader should not attempt to rescore the slide from a brief phrase in the report; the laboratory’s criteria and the pathologist’s assessment are needed to understand what a focal pattern means in that case.
Does CDX2-positive mean colon cancer?
No. A positive result can be one piece of evidence supporting intestinal differentiation, but it does not establish that a tumor began in the colon. CDX2 expression has been described in tumor types beyond colorectal tumors, including other intestinal tumors and some neuroendocrine neoplasms.
Free tools Windows power users keep installed
One-click scans. No signup required.
The pathologist weighs CDX2 with the specimen’s location, the tumor’s morphology (its appearance under the microscope), the patient’s history, and other tests. The stain may help assess a possible primary site, but no single marker should be treated as a binary origin test. A positive result should therefore be read as “this finding may support intestinal differentiation,” not “the primary site is proven.”
Rank #2
- 【IP68 Waterproof Multifunctinal Smart Watch】Torjalph fitness activity tracker smart watch is IP68 waterproof technology ,you can wear it when swimming,handwashing,it's rain-proof which means that you perform multiple exercise modes outside without worrying about sweat or rain corroding your fitness smart watch,and this watch equipped with a 230 mAh large capacity battery magnetic charging ,and this sports activity tracker watch can be used 5-7 days If fully charged.
- 【Larger 1.83'' Full Screen Watch & Multi-dial Selection】1.83 inch full HD color touch screen smart watch for men / women provides excellent 240*284 resolution image quality ,This Bluetooth smart watch offers a better touch experience and remarkable immersion and ,more than 200 watch faces for you to choose from App"Da Fit ", you can change the dial style according to your mood to wear keeping the world on your wrist
- 【Accurate Activity Tracker Smart Watch 】sports watch activity tracker uses sweat and dust resistant breathable silicone strap, our Fitness Tracker Smart Watch for Android iOS Phones supports 12 sports modes,walking,running,bicycle,swimming,badminton,basketball,football,rope skipping. This bluetooth calls smart watch for men women is lightweight and stylish, bringing more convenient and relaxing sports experience while also providing more protection.
- 【Your 24 Hour Personal Daily Health Monitor】Fitness watch for women men full touch screen IP67 waterproof bluetooth smartwatch for Android iOS Phones with heart rate blood pressure monitor multifunction Andriod smart watch with steps counter sleep monitor sports fitness watch, monitoring blood oxygen saturation allows you to understand your physical condition in real time to track fitness progress ,to know your health status in time.
- 【More Functions Bluetooth Call Smart Watch】This fitness activity smart watch full screen for iPhone and Android phones includes a bunch of new features including:The bluetooth smart watch can hang up the phone, receive and display WhatsAPP /Text /Facebook /Twitter /Messenger reminder.Support sedentary reminder, alarm clock, stopwatch, timer,weather information,music control, remote camera control compatible with Android 5.0 and above or iOS 9.0 and above smartphones.
That distinction is especially useful when tissue has been sampled from a site that is not itself enough to show where the tumor originated. A marker result can contribute to the differential diagnosis—the set of possibilities being considered—but it does not replace the final interpretation of the tissue. The report’s diagnosis and comment, if present, are more informative than isolating the CDX2 line from the rest of the document.
Nor does a positive result necessarily mean the finding is unexpected or contradictory if the tumor arose outside the colon. CDX2 is associated with intestinal differentiation, and expression has been described across tumor types. The question for the pathologist is how the result fits with the morphology, specimen site, other selected markers, clinical history, and imaging—not whether a single stain can name the primary site by itself.
Does a negative result rule out colorectal cancer?
No. A negative CDX2 result does not rule out colorectal cancer. CDX2 loss and variation in staining across a tumor are recognized interpretive issues, and some colorectal cancers do not show the expected staining.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →A 2008 Modern Pathology study reported CDX2 negativity in 21.6% of microsatellite-instability-high (MSI-high) colorectal cancers in its cohort. This is a cohort-specific figure, not a universal rate, a measure of the test’s sensitivity for every patient, or an estimate of an individual patient’s probability. The practical point is that absence of CDX2 staining cannot, on its own, settle whether a tumor is colorectal in origin.
The figure applies to the MSI-high colorectal cancers included in that study; it should not be used as a prediction for a particular person or generalized to every colorectal cancer, specimen, or laboratory. It illustrates why a negative stain must be interpreted in context. The pathologist may consider the overall appearance of the tumor, the site sampled, other marker results, and the clinical question being investigated.
A negative result can weaken one line of support for intestinal differentiation, but “weaken” is not the same as “exclude.” If the report is evaluating a possible colorectal primary, ask how CDX2 fits with the full diagnostic picture and whether the pathologist’s conclusion relies on additional findings. Do not infer that colorectal cancer has been ruled out solely because the CDX2 line says negative.
How CDX2 fits with the rest of the pathology workup
A primary-site interpretation draws on several kinds of evidence. The final report may combine the tissue’s morphology and site with CDX2, other immunostains, clinical history, imaging, and any molecular findings that are relevant to the case. These sources of evidence answer related but different questions; they should be considered together rather than replaced by one stain.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errors| Evidence considered | What it contributes | What it cannot establish alone |
|---|---|---|
| Morphology and specimen site | The tumor’s microscopic appearance and where the sample was taken help frame the diagnostic question. | Neither should be replaced by a CDX2 result interpreted in isolation. |
| CDX2 staining pattern | Whether tumor cells show the marker associated with intestinal differentiation, including the pattern described by the laboratory. | A definitive primary site or complete diagnosis. |
| CK7, CK20, and other selected stains | Additional marker results may help the pathologist assess the differential diagnosis alongside CDX2. | A stand-alone answer without the other findings and clinical context. |
| Clinical history and imaging | Information about the patient and the distribution of disease can inform how the tissue findings are interpreted. | A substitute for the pathology interpretation of the sampled tissue. |
| Separate molecular tests | When indicated, they may address questions that an IHC stain does not answer. | They should not be assumed from CDX2 staining. |
CK7 and CK20 are among the markers discussed alongside CDX2 in this context, but which additional stains are used depends on the diagnostic question. The report’s interpretation matters: a list of marker results without the pathologist’s assessment may not explain how the findings fit together.
Rank #3
- [Low Noise High Fidelity] New bee guitar cord with 22AWG oxygen-free-copper center conductors provides enhanced signal transfer, the PVC insulation material and the high-density stranded copper double shield provide noise rejection for quiet operation
- [Ideal for Choice] New bee 1/4 straight and right angle metal connectors, ensures a secure connection in any instrument, pedal, or amp jack. L shape great fro on stage guitar stands
- [Wide Compatible] Suitable for mixer, power amplifier, microphone, effector, decoder, equalizer, electoronic organ, electric guitar, electric bass and other electronic equipments. Widely used in the installation of smart home, karaoke speaker, professional stage audio, etc
- [Easy Disassemble] Making incidental repairs quick and easy! Very nice, flexible cable
- [Dont Hesite to Order] 24 hours customer services and professional technology team are standing by
These evidence types are not interchangeable. Morphology describes what the tumor looks like under the microscope; specimen site identifies where the sample was taken; the stain reports whether the tumor cells show a marker under particular assay and scoring criteria. History and imaging add information about the patient and disease distribution. Any separate molecular findings address their own questions. A pathologist integrates these pieces rather than treating one as a substitute for all the others.
The combination of findings is also why a short marker list can be hard to interpret without the report’s conclusion. CK7 and CK20 may be used with CDX2 as part of assessing a differential diagnosis, but a fixed CK7/CK20 pattern should not be treated as a universal rule for identifying a primary site. Look for the pathologist’s explanation of how the selected stains work together in the specific specimen.
CDX2 is not MMR or MSI testing
CDX2 IHC is separate from mismatch-repair (MMR) protein IHC and microsatellite-instability (MSI) testing. A CDX2 result alone does not report whether a tumor is MMR-deficient or MSI-high. It also does not establish Lynch syndrome risk or determine eligibility for immune checkpoint therapy.
Those questions require the relevant separate tests and clinical interpretation. The College of American Pathologists’ MMR/MSI guideline addresses those tests and their role in selecting patients for immune checkpoint therapy; it is not a guideline for interpreting CDX2 as a treatment marker. Look for MMR or MSI results elsewhere in the pathology record if those questions are relevant, or ask whether testing was performed or is indicated.
The fact that a tumor can be MSI-high and lack CDX2 staining does not make the stains equivalent. The 2008 Modern Pathology finding describes CDX2 negativity in a subset of MSI-high colorectal cancers; it does not mean CDX2 reports MSI status. A reader needs the actual MMR or MSI result to know what those tests found.
This separation matters because different tests are used to answer different clinical questions. CDX2 contributes information about a marker associated with intestinal differentiation. MMR protein IHC and MSI testing address mismatch repair or microsatellite instability, and the CAP guideline discusses their role in selecting patients for immune checkpoint therapy. A CDX2-positive or CDX2-negative result cannot stand in for those tests or determine their implications.
What a CDX2 result does not tell you
A single CDX2 line cannot supply the full meaning of a cancer diagnosis. It does not, by itself, determine:
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
- the tumor’s primary site;
- the complete type or extent of cancer;
- the cancer stage or prognosis;
- which treatment is appropriate;
- the tumor’s MMR or MSI status, Lynch syndrome risk, or immunotherapy eligibility.
Those conclusions depend on the final pathology diagnosis and the relevant combination of morphology, other stains, imaging, clinical history, and any indicated molecular tests. The colorectal biomarker guideline published by ASCP, CAP, AMP, and ASCO concerns biomarkers used in colorectal cancer management and emphasizes understandable results and interpretations with relevant limitations. It is not a CDX2-specific treatment guideline.
Rank #4
- Digital Family Calendar: BSIMB digital calendar wall touch screen puts an end to your chaotic life. Designed for busy families, the digital calendar keeps you organised and in step with your family. Assign different colours and tasks to each family member to make family scheduling easier and more intuitive.
- Easy Setup and Auto-Sync: Plug in, connect to WLAN and auto-syn your electric calendar in minutes. Digital wall calendar compatible with Google calendar, iCloud calendar, Outlook calendar, Cozi calendar and Yahoo calendar. Add events directly on the device or through the ecalendar app. Electronic calendar stays current whether you're at work or traveling—no manual updates needed.
- All-In-One Home Assistant: Smart calendar builds habits and encourage independence with personalised chores. Display daily meal plan to reduce the daily ‘What's for dinner?’ stress. To-do lists keep track of everything you want. Turning chores into valuable achievements with stars and rewards, making life easier and more enjoyable.
- Manage Anytime Anywhere: BSIMB electronic calendar for family stay connected with the powerful ecalendar app. Access and manage your digital wall calendar anytime, anywhere with free features like stars & rewards, photo screensaver, chore charts, meals plans, to-do lists etc. Electronic planner paid features like Magic Import tailor advanced tools for users with special needs.
- Stay in Touch with Loved Ones: Share photos or videos from your phone to electronic wall calendar with app, instantly update your life moment, and keep in touch with your family, especially those who are far away; you can also surprise your smart calendar digital wall by sending him a wish card; it's also great for keeping tech-illiterate elders in touch with the youngsters.
The College of American Pathologists’ 2017 colorectal biomarker guideline contains 21 statements: eight recommendations, ten expert consensus opinions, and three no-recommendation statements. CAP describes the evidence review for the guideline as covering more than 4,000 articles. Those figures describe the scope of that colorectal biomarker guideline; they do not make it a CDX2-specific guideline and do not turn an individual CDX2 result into a treatment recommendation.
In practical terms, a marker result is one part of a diagnostic record. It cannot on its own provide the stage, prognosis, or treatment plan, and it does not establish whether a separate test was done. For those questions, use the final pathology diagnosis and discussion with the treating clinician, who can relate the report to the clinical history, imaging, and any additional findings.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How to read the result in your report
- Find the final diagnosis first. Read the diagnosis and any comment or interpretation before trying to infer meaning from the CDX2 line alone.
- Check what tissue was tested. Note where the specimen came from and whether the report is describing a primary tumor or a sample from another site. The specimen location is part of the context for interpreting the stain.
- Read the exact CDX2 wording. Look for whether the result is called positive, negative, focal, or patchy, and whether the report describes the extent or intensity of staining.
- Review the other stains and their interpretation. See whether CK7, CK20, or other markers were used and how the pathologist says they fit the differential diagnosis.
- Keep separate tests separate. Look for MMR or MSI results independently; do not infer them from CDX2.
- Ask how the findings fit together. If the report does not make the primary-site interpretation clear, ask the treating clinician to explain the overall diagnosis or request clarification from the pathologist.
As you read, distinguish the result itself from the interpretation. The result may describe staining as positive, negative, focal, or patchy. The interpretation explains what the pathologist concludes when that observation is considered with the other findings. If the report includes a comment, it may provide important context; if it does not, the treating clinician can help you understand how the final diagnosis was reached or seek clarification from the pathologist.
Also note what the report does not say. A CDX2 result does not imply that MMR/MSI testing was performed, and it does not provide a separate test result by implication. If the report contains a list of stains but no clear explanation of their combined meaning, ask for the overall diagnostic interpretation rather than trying to assign a primary site from the list yourself.
Questions to ask the care team
- What is the final diagnosis in the report, and what does it say about the likely primary site?
- Is CDX2 staining present in the tumor cells? If so, is it diffuse, focal, or patchy, and how did the laboratory classify it?
- Which other stains were performed, and how do their results support or challenge the interpretation?
- Is CDX2 being used to evaluate a possible primary site, or is it answering a different diagnostic question?
- Are MMR or MSI results reported separately, and are any additional tests relevant to this case?
These questions help distinguish the stain result from the pathologist’s overall conclusion. Your treating clinician can explain how the complete pathology report relates to imaging, clinical history, and next steps.
You can also ask whether the report’s use of “focal” or “patchy” reflects the laboratory’s scoring criteria, whether internal controls were satisfactory, and whether the finding changed the final interpretation. If a result is negative, ask whether the pathologist considered that result alongside the specimen’s morphology and other tests rather than treating it as a stand-alone exclusion.
Frequently asked questions
What does CDX2 positive mean?
It means tumor cells show staining for CDX2 under the laboratory’s assay and scoring criteria. CDX2 is associated with intestinal differentiation, so a positive result may support an intestinal origin in context. It does not by itself prove that the tumor began in the colon or establish a complete diagnosis.
What does CDX2 negative mean?
It means the tumor cells did not show the expected staining under the laboratory’s criteria. This removes one possible line of support for intestinal differentiation but does not rule out colorectal cancer. The result must be interpreted with morphology, specimen site, other stains, and clinical information.
Does CDX2 positive mean colon cancer?
No. CDX2 expression is not exclusive to colorectal tumors and has been described in other intestinal tumors and some neuroendocrine neoplasms. A positive result can contribute to considering a possible primary site, but it is not a binary origin test.
Can colorectal cancer be CDX2 negative?
Yes. CDX2 loss is a recognized interpretive issue. A 2008 Modern Pathology study reported that 21.6% of MSI-high colorectal cancers in its cohort were CDX2-negative. That cohort-specific figure is not a universal rate or a prediction for an individual patient.
Does CDX2 tell me whether a tumor is MSI-high or MMR-deficient?
No. CDX2 IHC is separate from MMR protein IHC and MSI testing. The CDX2 result alone does not report MMR or MSI status, Lynch syndrome risk, or immunotherapy eligibility. Look for the separate results or ask the care team whether those tests were performed or are indicated.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteFrequently Asked Questions
What does CDX2 positive mean?
It means tumor cells show staining for CDX2 under the laboratory’s assay and scoring criteria. CDX2 is associated with intestinal differentiation, so a positive result may support an intestinal origin in context, but it does not prove a colorectal primary.
What does CDX2 negative mean?
It means the tumor cells did not show the expected staining under the laboratory’s criteria. It weakens one line of support for intestinal differentiation but does not rule out colorectal cancer.
Does CDX2 positive mean colon cancer?
No. CDX2 is not exclusive to colorectal tumors. The pathologist considers it with morphology, specimen site, other stains, history, and imaging; no single marker establishes the primary site.
Can colorectal cancer be CDX2 negative?
Yes. A 2008 Modern Pathology study reported CDX2 negativity in 21.6% of MSI-high colorectal cancers in its cohort. That figure is cohort-specific, not a universal rate or an individual prediction.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Does CDX2 tell me whether a tumor is MSI-high or MMR-deficient?
No. CDX2 IHC is separate from MMR protein IHC and MSI testing. A CDX2 result alone does not report MMR or MSI status, Lynch syndrome risk, or immunotherapy eligibility.
The Bottom Line
CDX2 is a marker associated with intestinal differentiation, not a stand-alone diagnosis or a test that proves or excludes colorectal cancer. Read the exact staining pattern alongside the full pathology interpretation, specimen site, other findings, and any separate MMR/MSI results; ask the care team how those pieces fit together.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
